For the Inventor, By the Inventor

Enter assignee name

Brisbane, CA, United States of America

Unity Biotechnology, Inc.

Calculating rank

USPTO Granted Patents = 41

% Expired Patents = 19.5

CIPO Patents = 1

EPO Patents = 7

Forward Citations = 132

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Nathaniel E David (25 out of 42 patents)

Remi-Martin Laberge (20 out of 24 patents)

Judith Campisi (17 out of 30 patents)

4. James L Kirkland (16 out of 21 patents)

5. Yi Zhu (16 out of 17 patents)

6. Tamar Tchkonia (16 out of 21 patents)

7. Marco Demaria (15 out of 19 patents)

8. Jan M A Van Deursen (13 out of 15 patents)

9. Alain Philippe Vasserot (12 out of 98 patents)

10. Darren J Baker (11 out of 13 patents)

11. Bennett G Childs (9 out of 9 patents)

12. Anne-Marie Beausoleil (8 out of 34 patents)

13. Ryan Hudson (8 out of 8 patents)

14. Albert Davalos (7 out of 7 patents)

15. Jamie Dananberg (4 out of 4 patents)

Core Competencies:

Senescent Cells

Bcl-xL Inhibitors

Ocular Disease

Cancer Treatment

Cardiovascular Disease

Neurodegenerative Conditions

Angiogenesis Inhibition

Gene Vector

Peptide-Based Inhibitors

Drug Conjugates

Pulmonary Conditions

Osteoarthritis

41 patents: Sort by Forward Citations

1. 12285427 - Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor (2025-04-29),

2. 12221433 - Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2025-02-11),

3. 12195542 - Antibodies directed to Tie-2 and methods of use (2025-01-14),

4. 11980616 - Treating liver disease by selectively eliminating senescent cells (2024-05-14),

5. 11963957 - Treating cardiovascular disease by selectively eliminating senescent cells (2024-04-23),

6. 11951115 - Methods of treating retinal vasculopathies (2024-04-09),

7. 11865123 - Methods of inhibiting pathological angiogenesis (2024-01-09),

8. 11351167 - Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue (2022-06-07),

9. 11129838 - Methods of inhibiting pathological angiogenesis (2021-09-28),

10. 11111259 - Acylsulfonamide derivatives for treating senescence-associated diseases and disorders (2021-09-07),

11. 10981892 - Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2021-04-20),

12. 10745445 - Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells (2020-08-18),

13. 10745429 - Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2020-08-18),

14. 10738042 - Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2020-08-11),

15. 10717722 - Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2020-07-21),

Company Overview

Unity Biotechnology, Inc. is a biotechnology company based in Brisbane, California, focused on developing therapeutics targeting senescent cells to address age-related diseases. The company specializes in innovative approaches such as Bcl-xL inhibitors and peptide-based inhibitors, aiming to treat conditions like ocular diseases, neurodegenerative disorders, and atherosclerosis. Unity's research also explores gene vector therapy and the mechanisms of pathological angiogenesis, positioning it at the forefront of regenerative medicine and aging research.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

41 Patents

#4 in Brisbane, CA

#1,993 in California

#8,449 in US

#16,731 in the World

Brisbane, CA, United States of America

Unity Biotechnology, Inc.

Forward Citations = 132

36 inventors:

Nathaniel E David (25 out of 42 patents)

Remi-Martin Laberge (20 out of 24 patents)

Judith Campisi (17 out of 30 patents)

4. James L Kirkland (16 out of 21 patents)

5. Yi Zhu (16 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Unity Biotechnology, Inc.. Retrieved from https://idiyas.com/company/unity-biotechnology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…